Outpace Bio halts Phase 1 ovarian cancer CAR‑T trial

Outpace Bio announced that it has stopped its Phase 1 trial of OPB-101, an autologous CAR‑T therapy targeting mesothelin in ovarian cancer.

The company said the trial will no longer enroll patients and further development of the program is being discontinued, highlighting the difficulty of advancing early‑stage cell therapies.

In the same briefing, Incyte reported data at the ESMO meeting that attracted interest, though specific results were not detailed in the release.

Brief mentions were also made of updates from Genmab, Rumi, Prana and Fractyl, but no further information was provided.